ArticleJournal of experimental & clinical cancer research : CR2024
IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas.
G Sari et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this papercites it